SCLX实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (12 Jun 2024 @ 04:00):

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain...

Stats
今日成交量	1.50M
平均成交量	886 939
市值	240.98M
EPS	$-0.240 ( Q1 \| 2024-05-13 )
下一个收益日期	( $-0.180 ) 2024-08-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.020 (Sector) 42.63 (Industry) 61.14
ATR14	$0.00700 (0.53%)

CRXT -31.16%

MIRA -0.05%

SCLX 18.75%

SCLXW 7.07%

Insider Trading

Date	Person	Action	Amount	type
2024-05-17	Ji Henry	Buy	50 000	Common Stock
2024-05-17	Chun Jay	Buy	57 500	Common Stock
2024-05-17	Shah Jaisim	Buy	56 939	Common Stock
2024-05-16	Shah Jaisim	Buy	83 061	Common Stock
2024-05-17	Ma Stephen Hoi	Buy	14 140	Common Stock

INSIDER POWER
-85.53
Last 53 transactions
Buy: 18 104 987 \| Sell: 160 710 385

音量相关性

長: -0.03 (neutral)

短: -0.70 (moderate negative)

Signal:(47.735) Neutral

Scilex Holding Company 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Scilex Holding Company 相关性 - 货币/商品

0.21
( neutral )

-0.06
( neutral )

0.00
( neutral )

0.51
( weak )

-0.39
( neutral )

Scilex Holding Company 财务报表

Annual	2023
营收:	$46.74M
毛利润:	$26.92M (57.58 %)
EPS:	$-0.880

FY	2023
营收:	$46.74M
毛利润:	$26.92M (57.58 %)
EPS:	$-0.880

FY	2022
营收:	$38.03M
毛利润:	$27.24M (71.61 %)
EPS:	$-0.170

Financial Reports:

No articles found.

Scilex Holding Company Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Scilex Holding Company

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.